{"id":19725,"date":"2023-06-22T23:30:00","date_gmt":"2023-06-22T23:30:00","guid":{"rendered":"https:\/\/www.prnasia.com\/story\/archive\/4137475_CN37475_0"},"modified":"2023-06-22T23:30:00","modified_gmt":"2023-06-22T23:30:00","slug":"sk-pharmteco-doubles-viral-vector-production-capacity-in-europe","status":"publish","type":"post","link":"https:\/\/transmediavictoria.net.au\/?p=19725","title":{"rendered":"SK pharmteco doubles viral vector production capacity in Europe"},"content":{"rendered":"<table name=\"logo_release\" border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/1979547\/SK_Inc_Logo.jpg?p=medium600\" border=\"0\" alt title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\"><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<ul type=\"disc\">\n<li>Yposkesi, SK pharmteco&#8217;s clinical and commercial viral vector manufacturing subsidiary for Cell and Gene Therapy (C&amp;GT), completes its second bioproduction facility and doubles its manufacturing footprint to <span class=\"xn-money\">10,000m<\/span><sup>2<\/sup>, one of the largest in <span class=\"xn-location\">Europe<\/span><\/li>\n<li>Operation of the second facility to kick start in 2024<\/li>\n<\/ul>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">SEOUL, South Korea<\/span>, June 23, 2023 \/PRNewswire\/ &#8212; SK pharmteco, SK Inc.&#8217;s contract development manufacturing organization (CDMO) for pharmaceuticals, successfully completed its second facility for Cell and Gene Therapies (C&amp;GT) manufacturing in <span class=\"xn-location\">Europe<\/span>. With this milestone, SK pharmteco is rapidly expanding its presence in the global market.<\/span><\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder7547\" readability=\"10\">\n<p><a href=\"https:\/\/mma.prnasia.com\/media2\/2109137\/1__SK_____________________2.html\" target=\"_blank\" rel=\"nofollow noopener\"><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/2109137\/1__SK_____________________2.jpg?p=medium600\" title=\"Yposkesi, SK pharmteco\u2019s commercial viral vector manufacturing subsidiary for C&amp;GT in France, successfully completed the construction of its second industrial bioproduction site for C&amp;GT manufacturing\" alt=\"Yposkesi, SK pharmteco\u2019s commercial viral vector manufacturing subsidiary for C&amp;GT in France, successfully completed the construction of its second industrial bioproduction site for C&amp;GT manufacturing\"><\/a><br \/><span>Yposkesi, SK pharmteco\u2019s commercial viral vector manufacturing subsidiary for C&gt; in France, successfully completed the construction of its second industrial bioproduction site for C&gt; manufacturing<\/span><\/p>\n<\/p><\/div>\n<p>SK pharmteco announced on <span class=\"xn-chron\">June 22nd<\/span> that Yposkesi, its commercial viral vector manufacturing subsidiary for C&amp;GT in <span class=\"xn-location\">France<\/span>, successfully completed the construction of its second industrial bioproduction site for C&amp;GT manufacturing.<\/p>\n<p>Yposkesi&#8217;s second bioproduction site is situated in its Genopole campus, the largest biotech cluster in <span class=\"xn-location\">France<\/span>. The newly completed site is a <span class=\"xn-money\">5,000 m<\/span><sup>2 <\/sup>facility designed in accordance with current Good Manufacturing Practices (GMP) guidelines of the US and <span class=\"xn-location\">Europe<\/span>. Together with the first bioproduction site, which is also located in the Genopole campus, Yposkesi now boasts one of <span class=\"xn-location\">Europe&#8217;s<\/span> largest biomanufacturing facility for C&amp;GT that spans <span class=\"xn-money\">10,000 m<\/span><sup>2<\/sup>.<\/p>\n<p>The new site specializes in the bioproduction of Adeno-associated virus (AAV) and Lentiviral Vector (LV) \u2013 the widely used viral vectors in the field of cell and gene therapies, spanning from clinical to commercial applications.<\/p>\n<p>Yposkesi is among only a small group of global CDMOs with decades of bioprocessing experience and expertise. It is one of the few in <span class=\"xn-location\">Europe<\/span> to operate two bioproduction platforms for the most used viral vectors: Adeno Associated Virus (AAV) and Lentiviral Vector (LV). It has more experience than most players at producing viral vectors at an industrial scale.<\/p>\n<p>With commitments from multiple clients already secured for the second facility, the company is preparing for mass production in 2024. According to the global research firm MarketsandMarkets, the global viral vector market, estimated at <span class=\"xn-money\">$5.5 billion<\/span> (<span class=\"xn-money\">KRW 7.5 trillion<\/span>) in 2023 and forecast to reach <span class=\"xn-money\">$12.8 billion<\/span> (<span class=\"xn-money\">KRW 16.5 trillion<\/span>) by 2028, is projected to increase by a compound annual growth rate (CAGR) of approximately 18%.<\/p>\n<p>Yposkesi is poised to enhance its global presence due to the increasing demand for viral vectors and few cGMP-compliant facilities for large-scale production.<\/p>\n<p>Furthermore, Yposkesi is rapidly expanding its presence in the anti-cancer and immune cell therapy market with the introduction of LentiSure\u2122, a CAR T-cell platform designed to optimize higher yields. The facility is designed with six USP (Upstream Process) and two DSP (Downstream Process) clean rooms. This more than triples Yposkesi&#8217;s bioreactor capacity from 2,000 L to 7,000 L and reduces the turnaround on projects from 18- to 12-months. It has fill and finish capacities with semi-automated suites for a total of 12,000 vials per year.<\/p>\n<p>Lentivirus, a prominent viral vector utilized in gene therapy and cell-based immune anticancer drugs, has experienced a surge in demand, driven by the expanding CAR-T cell therapy* market. Yposkesi, leveraging its high-yield cell culture\/harvesting capabilities and cost competitiveness, has successfully ensured exceptional quality and time to market delivery of Lentiviral Vectors.<\/p>\n<p>&#8220;It is with great pleasure and pride that today we open the new Yposkesi viral vector manufacturing facility,&#8221; said Alain Lamproye, CEO of Yposkesi. &#8220;This twin site enables us to stay up to pace with demand by producing larger quantities of C&amp;GT products approved for commercialization. The facility&#8217;s state-of-the-art design will allow us, in collaboration with our clients, to manufacture advanced therapies more efficiently and cost-effectively in line with their C&amp;GT pipelines and commitments, making these treatments more accessible to patients.&#8221;<\/p>\n<p>&#8220;We anticipate Yposkesi to become a leading global Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) through the synergy achieved with the Center for Breakthrough Medicines (CBM), a US-based cell and gene therapy CDMO and a subsidiary of SK pharmteco,&#8221; said <span class=\"xn-person\">Yeontae Kim<\/span>, Head of the Bio Investment Center at SK Inc.<\/p>\n<p>In 2019, SK Inc. established SK pharmteco, a globally integrated contract development and manufacturing organization (CDMO) for pharmaceuticals. SK pharmteco operates seven production facilities and five R&amp;D centers strategically located across <span class=\"xn-location\">the United States<\/span>, <span class=\"xn-location\">Europe<\/span>, and Korea. As a subsidiary of SK Inc., SK pharmteco expanded its presence in the rapidly growing biopharmaceutical industry by acquiring Yposkesi in 2021, gaining entry into the cell and gene therapy market. Furthermore, in 2022, SK pharmteco became the second largest shareholder of the Center for Breakthrough Medicines, a leading cell and gene therapy CDMO in <span class=\"xn-location\">the United States<\/span>, thereby securing state-of-the-art production facilities for cell and gene therapy in both <span class=\"xn-location\">Europe<\/span> and <span class=\"xn-location\">the United States<\/span>.<\/p>\n<p><b>About Yposkesi<\/b><\/p>\n<p>Yposkesi, an SK pharmteco company, is one of <span class=\"xn-location\">Europe&#8217;s<\/span> largest CDMOs for viral vector manufacturing in Cell and Gene Therapies (C&amp;GT). Yposkesi&#8217;s 30+ years&#8217; expertise in viral vectors enables it to partner successfully with both biotech companies and big pharma in producing quality preclinical to commercial batch drug therapy products within a full-service environment. The company sustainably invests in bioprocessing innovation in order to deliver high quality gene-modified cell therapies and <i>in vivo <\/i>gene therapy projects.<\/p>\n<p>Yposkesi employs around 200 people and is headquartered at the Genopole Campus at Evry-Courcouronnes (South of <span class=\"xn-location\">Paris<\/span>), <span class=\"xn-location\">France<\/span>. <a href=\"http:\/\/www.yposkesi.com\/\" target=\"_blank\" rel=\"nofollow noopener\">www.yposkesi.com<\/a><\/p>\n<p><b>About SK pharmteco<\/b><\/p>\n<p>Headquartered in <span class=\"xn-location\">Rancho Cordova, California<\/span>, SK pharmteco is a global CDMO and a subsidiary of SK Inc., the strategic investment company for SK Group, <span class=\"xn-location\">South Korea&#8217;s<\/span> second-largest conglomerate. SK pharmteco was established in 2019 by consolidating highly complementary CDMO business operations. SK pharmteco has established a well-balanced business portfolio by engaging in small molecule &amp; cell and gene therapy to capture both the robust and exponential growth of each market. Most recently, SK pharmteco became the second-largest shareholder of the Center for Breakthrough Medicines through its investment in <span class=\"xn-chron\">March 2022<\/span>. SK pharmteco currently operates seven global manufacturing sites in <span class=\"xn-location\">the United States<\/span>, <span class=\"xn-location\">Europe<\/span>, and <span class=\"xn-location\">South Korea<\/span>, along with five R&amp;D centers. <a href=\"http:\/\/www.skpharmteco.com\/\" target=\"_blank\" rel=\"nofollow noopener\">www.skpharmteco.com<\/a><\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder2763\" readability=\"10\">\n<p><a href=\"https:\/\/mma.prnasia.com\/media2\/2109138\/2__SK_____________________2.html\" target=\"_blank\" rel=\"nofollow noopener\"><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/2109138\/2__SK_____________________2.jpg?p=medium600\" title=\"Yposkesi CEO, Alain Lamproye and CEO of SK phamteco, Joerg Ahlgrimm at the Yposkesi\u2019s completed second plant.\" alt=\"Yposkesi CEO, Alain Lamproye and CEO of SK phamteco, Joerg Ahlgrimm at the Yposkesi\u2019s completed second plant.\"><\/a><br \/><span>Yposkesi CEO, Alain Lamproye and CEO of SK phamteco, Joerg Ahlgrimm at the Yposkesi\u2019s completed second plant.<\/span><\/p>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Yposkesi, SK pharmteco&#8217;s clinical and commercial viral vector manufacturing subsidiary for Cell and Gene Therapy (C&amp;GT), completes its second bioproduction facility and doubles its manufacturing footprint to 10,000m2, one of the largest in Europe Operation of the second facility to kick start in 2024 SEOUL, South Korea, June 23, 2023 \/PRNewswire\/ &#8212; SK pharmteco, SK [&hellip;]<\/p>\n","protected":false},"author":8,"featured_media":19726,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-19725","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>SK pharmteco doubles viral vector production capacity in Europe - My Blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/transmediavictoria.net.au\/?p=19725\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SK pharmteco doubles viral vector production capacity in Europe - My Blog\" \/>\n<meta property=\"og:description\" content=\"Yposkesi, SK pharmteco&#8217;s clinical and commercial viral vector manufacturing subsidiary for Cell and Gene Therapy (C&amp;GT), completes its second bioproduction facility and doubles its manufacturing footprint to 10,000m2, one of the largest in Europe Operation of the second facility to kick start in 2024 SEOUL, South Korea, June 23, 2023 \/PRNewswire\/ &#8212; SK pharmteco, SK [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/transmediavictoria.net.au\/?p=19725\" \/>\n<meta property=\"og:site_name\" content=\"My Blog\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-22T23:30:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnasia.com\/media2\/1979547\/SK_Inc_Logo.jpg?p=medium600\" \/>\n<meta name=\"author\" content=\"admin_tony\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin_tony\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=19725#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=19725\"},\"author\":{\"name\":\"admin_tony\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"headline\":\"SK pharmteco doubles viral vector production capacity in Europe\",\"datePublished\":\"2023-06-22T23:30:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=19725\"},\"wordCount\":1026,\"image\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=19725#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/transmediavictoria.net.au\\\/wp-content\\\/uploads\\\/2023\\\/06\\\/sk-pharmteco-doubles-viral-vector-production-capacity-in-europe.jpg\",\"articleSection\":[\"Business News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=19725\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=19725\",\"name\":\"SK pharmteco doubles viral vector production capacity in Europe - My Blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=19725#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=19725#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/transmediavictoria.net.au\\\/wp-content\\\/uploads\\\/2023\\\/06\\\/sk-pharmteco-doubles-viral-vector-production-capacity-in-europe.jpg\",\"datePublished\":\"2023-06-22T23:30:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=19725#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=19725\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=19725#primaryimage\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/wp-content\\\/uploads\\\/2023\\\/06\\\/sk-pharmteco-doubles-viral-vector-production-capacity-in-europe.jpg\",\"contentUrl\":\"https:\\\/\\\/transmediavictoria.net.au\\\/wp-content\\\/uploads\\\/2023\\\/06\\\/sk-pharmteco-doubles-viral-vector-production-capacity-in-europe.jpg\",\"width\":599,\"height\":400},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=19725#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SK pharmteco doubles viral vector production capacity in Europe\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\",\"name\":\"My Blog\",\"description\":\"My WordPress Blog\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\",\"name\":\"admin_tony\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"caption\":\"admin_tony\"},\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?author=8\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SK pharmteco doubles viral vector production capacity in Europe - My Blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/transmediavictoria.net.au\/?p=19725","og_locale":"en_US","og_type":"article","og_title":"SK pharmteco doubles viral vector production capacity in Europe - My Blog","og_description":"Yposkesi, SK pharmteco&#8217;s clinical and commercial viral vector manufacturing subsidiary for Cell and Gene Therapy (C&amp;GT), completes its second bioproduction facility and doubles its manufacturing footprint to 10,000m2, one of the largest in Europe Operation of the second facility to kick start in 2024 SEOUL, South Korea, June 23, 2023 \/PRNewswire\/ &#8212; SK pharmteco, SK [&hellip;]","og_url":"https:\/\/transmediavictoria.net.au\/?p=19725","og_site_name":"My Blog","article_published_time":"2023-06-22T23:30:00+00:00","og_image":[{"url":"https:\/\/mma.prnasia.com\/media2\/1979547\/SK_Inc_Logo.jpg?p=medium600","type":"","width":"","height":""}],"author":"admin_tony","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin_tony","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/transmediavictoria.net.au\/?p=19725#article","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/?p=19725"},"author":{"name":"admin_tony","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"headline":"SK pharmteco doubles viral vector production capacity in Europe","datePublished":"2023-06-22T23:30:00+00:00","mainEntityOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=19725"},"wordCount":1026,"image":{"@id":"https:\/\/transmediavictoria.net.au\/?p=19725#primaryimage"},"thumbnailUrl":"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2023\/06\/sk-pharmteco-doubles-viral-vector-production-capacity-in-europe.jpg","articleSection":["Business News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/transmediavictoria.net.au\/?p=19725","url":"https:\/\/transmediavictoria.net.au\/?p=19725","name":"SK pharmteco doubles viral vector production capacity in Europe - My Blog","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/#website"},"primaryImageOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=19725#primaryimage"},"image":{"@id":"https:\/\/transmediavictoria.net.au\/?p=19725#primaryimage"},"thumbnailUrl":"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2023\/06\/sk-pharmteco-doubles-viral-vector-production-capacity-in-europe.jpg","datePublished":"2023-06-22T23:30:00+00:00","author":{"@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"breadcrumb":{"@id":"https:\/\/transmediavictoria.net.au\/?p=19725#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/transmediavictoria.net.au\/?p=19725"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/transmediavictoria.net.au\/?p=19725#primaryimage","url":"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2023\/06\/sk-pharmteco-doubles-viral-vector-production-capacity-in-europe.jpg","contentUrl":"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2023\/06\/sk-pharmteco-doubles-viral-vector-production-capacity-in-europe.jpg","width":599,"height":400},{"@type":"BreadcrumbList","@id":"https:\/\/transmediavictoria.net.au\/?p=19725#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/transmediavictoria.net.au\/"},{"@type":"ListItem","position":2,"name":"SK pharmteco doubles viral vector production capacity in Europe"}]},{"@type":"WebSite","@id":"https:\/\/transmediavictoria.net.au\/#website","url":"https:\/\/transmediavictoria.net.au\/","name":"My Blog","description":"My WordPress Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/transmediavictoria.net.au\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7","name":"admin_tony","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","caption":"admin_tony"},"url":"https:\/\/transmediavictoria.net.au\/?author=8"}]}},"_links":{"self":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/19725","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=19725"}],"version-history":[{"count":0,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/19725\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/media\/19726"}],"wp:attachment":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=19725"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=19725"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=19725"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}